Document:

Form of Warrant issued to investors and agents

 EXHIBIT 4.7 
 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE APRIL 25, 2010. 
 WITHOUT PRIOR WRITTEN APPROVAL OF THE TSX VENTURE EXCHANGE (“TSXV”) AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD,
TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF THE TSXV OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL APRIL 25, 2010. 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) OR OTHER APPLICABLE SECURITIES LAWS.
THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) IN ACCORDANCE WITH THE PROVISIONS OF REGULATIONS S, RULE 901 THROUGH RULE
905, AND PRELIMINARY NOTES UNDER THE U.S. SECURITIES ACT OR (2) PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT. 
 THIS WARRANT CERTIFICATE, AND THE WARRANTS EVIDENCED HEREBY, WILL BE VOID AND OF NO VALUE UNLESS EXERCISED ON OR BEFORE 4:00 P.M. (VANCOUVER TIME) ON
DECEMBER 24, 2011. 
 MED BIOGENE INC. 
 a corporation amalgamated under the laws of the Province of British Columbia 
 and
having its principal office at 
 #300 - 2386 East Mall, Gerald McGavin Building 
 Vancouver, British Columbia 
  

			
	NO. G-	 	WARRANTS
		
		 	Each entitling the holder to acquire one (1) common share in the capital of Med BioGene Inc., subject to adjustment as set forth herein, in accordance with the terms and
conditions set forth herein.

 THIS IS TO CERTIFY THAT for value received <NAME>, <ADDRESS> (the
“Holder”) is the registered holder of the number of Warrants stated above and is entitled for each whole Warrant represented hereby to purchase one (1) common share (each a “Share” and collectively the “Shares”) in
the capital of Med BioGene Inc. (the “Company”) at any time and from time to time from the date of issue hereof up to and including 4:00 p.m. (Vancouver Time) on December 24, 2011 (the “Expiry Time”), at a price per
Share equal to $0.18, subject to adjustment as hereinafter provided (the “Exercise Price”), upon and subject to the following terms and conditions. 
 For purposes of this Warrant: 
  

	 	(i)	“Warrant Shares” means the Shares which are issuable upon the exercise from time to time of these Warrants; 

  

	 	(ii)	“$” means Canadian dollars. 

 These Warrants are issued under a subscription agreement between the Company and the Holder, inter alia, and accepted by the Company on December 24, 2009. 

 TERMS AND CONDITIONS 
  

	1.	The Warrants represented by this Warrant Certificate may not be exercised in the United States or by or on behalf of a U.S. Person nor will the Warrant Shares be
registered or delivered to an address in the United States, unless an exemption from registration under the U.S. Securities Act or the securities laws of any U.S. state is available, and with the prior consent of the Company (which will be delivered
promptly and will not be unreasonably withheld but which may be conditioned on delivery of a legal opinion in form and substance satisfactory to the Company). As used herein, the terms “United States” and “U.S. Person” have the
meanings ascribed to them in Regulation S under the U.S. Securities Act. 

 The Warrants represented by this
Warrant Certificate and the Warrant Shares issuable upon exercise of these Warrants are subject to certain resale restrictions under applicable securities legislation. The Holder is advised to seek professional advice as to applicable resale
restrictions. 
 Certificates representing the Warrant Shares issuable upon the exercise of these Warrants shall bear a legend in
form and substance to those appearing on the first page of this Warrant Certificate until no longer required by applicable securities legislation. 
  

	2.	If at any time after the day which is four months plus one day from the date hereof the closing price of the Shares on the TSX Venture Exchange, or such major stock
exchange or quotation system as the Shares are then trading or are listed, is greater than $0.30 for 20 or more consecutive trading days, the Company may give notice to the Holder that the Expiry Time has been accelerated and that the Warrants will
expire on the 20th business day following the date of such notice. 

  

	3.	At any time and from time to time at or prior to the Expiry Time, including any accelerated Expiry Time pursuant to Section 2 (the “Exercise Period”),
the Holder may exercise all or any number of whole Warrants represented hereby, upon delivering to the Company at its principal office noted above on this Warrant Certificate, together with a duly completed and executed subscription notice in the
form attached hereto (the “Subscription Notice”) evidencing the election of the Holder to exercise the number of Warrants set forth in the Subscription Notice (which shall not be greater than the number of Warrants represented by this
Warrant Certificate as adjusted from time to time pursuant to Sections 6 and 7 of this Warrant Certificate) and a certified cheque, money order or bank draft payable to the Company for the aggregate Exercise Price of all Warrants being exercised. If
the Holder is not exercising all Warrants represented by this Warrant Certificate, the Holder shall be entitled to receive, without charge, a new Warrant Certificate representing the number of Warrants which is the difference between the number of
Warrants represented by the then original Warrant Certificate and the number of Warrants being so exercised. 

  

	4.	The Holder shall be deemed to have become the holder of record of Warrant Shares on the date (the “Exercise Date”) on which the Company has received a
duly completed Subscription Notice, delivery of the Warrant Certificate and payment of the full aggregate Exercise Price in respect of the Warrants being exercised pursuant to such Subscription Notice; provided, however, that if such date is not a
business day in the City of Vancouver, British Columbia (a “Business Day”) then the Warrant Shares shall be deemed to have been issued and the Holder shall be deemed to have become the holder of record of the Warrant Shares on the next
following Business Day. Within seven (7) Business Days of the Exercise Date, the Company shall issue and deliver (or cause to be delivered) to the Holder, by registered mail or pre-paid courier to his, her or its address specified in the
register of the Company, one or more certificates for the appropriate number of issued and outstanding Warrant Shares. All costs, expenses, transfer taxes and other charges payable in connection with the issue and delivery of the Warrant Shares
shall be at the sole expense of the Company (other than withholding tax, if any). 

  

	5.	 The Company covenants and agrees that, until the Expiry Time, while any of the Warrants represented by this Warrant Certificate shall be outstanding,
it shall reserve and there shall remain unissued out of its authorized capital a sufficient number of Warrant Shares to satisfy the right of purchase herein provided, as

  

 2 

	 	 
such right of purchase may be adjusted pursuant to Sections 6 and 7 of this Warrant Certificate. The Company represents and warrants that all Warrant Shares which shall be issued upon the
exercise of the right to purchase herein provided for, upon payment of the aggregate Exercise Price at which such Warrant Shares may at that time be purchased pursuant to the provisions hereof, shall be issued as fully paid and non-assessable shares
and the holders thereof shall not be liable to the Company or its creditors in respect thereof. The Company further represents and warrants that this Warrant Certificate is a legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms. The Company covenants that it will make all filings under applicable laws required to be made by the Company in connection with the exercise of the Warrants and issue of Warrant Shares.

  

	6.	The Exercise Price (and the number of Warrant Shares purchasable upon exercise) shall be subject to adjustment from time to time in the events and in the manner
provided as follows: 

  

	 	(a)	Share Reorganization. If during the Exercise Period the Company shall: 

  

	 	(i)	issue Shares or securities exchangeable for or convertible into Shares to holders of all or substantially all of its then outstanding Shares by way of stock dividend or
other distribution, or 

  

	 	(ii)	subdivide, redivide or change its outstanding Shares into a greater number of Shares, or 

  

	 	(iii)	consolidate, reduce or combine its outstanding Shares into a lesser number of Shares, 

 (any of such events in these paragraphs (i), (ii) and (iii) being a “Share Reorganization”), then the Exercise Price
shall be adjusted as of the effective date or record date, as the case may be, at which the holders of Shares are determined for the purpose of the Share Reorganization by multiplying the Exercise Price in effect immediately prior to such effective
date or record date by a fraction, the numerator of which shall be the number of Shares outstanding on such effective date or record date before giving effect to such Share Reorganization and the denominator of which shall be the number of Shares
outstanding as of the effective date or record date after giving effect to such Share Reorganization (including, in the case where securities exchangeable for or convertible into Shares are distributed, the number of Shares that would have been
outstanding had such securities been fully exchanged for or converted into Shares on such record date or effective date). From and after any adjustment of the Exercise Price pursuant to this Section 6(a), the number of Warrant Shares
purchasable pursuant to this Warrant Certificate shall be adjusted contemporaneously with the adjustment of the Exercise Price by multiplying the number of Shares then otherwise purchasable on the exercise thereof by a fraction, the numerator of
which shall be the Exercise Price in effect immediately prior to the adjustment and the denominator of which shall be the Exercise Price resulting from such adjustment. 
  

	 	(b)	Rights Offering. If and whenever during the Exercise Period the Company shall fix a record date for the issue or distribution of rights, options or warrants to
all or substantially all of the holders of Shares under which such holders are entitled, during a period expiring not more than 45 days after the record date for such issue to subscribe for or purchase Shares or securities exchangeable for or
convertible into Shares at a price per share to the holder (or having a conversion price or exchange price per Share) of less than 95% of the Current Market Price (as defined in Section 7 hereof) for the Shares on such record date (any of such
events being called a “Rights Offering”), then the Exercise Price shall be adjusted effective immediately after the record date for the Rights Offering to a price determined by multiplying the Exercise Price in effect on such record date
by a fraction: 

  

	 	(i)	the numerator of which shall be the aggregate of: 

  

	 	(A)	the number of Shares outstanding as of the record date for the Rights Offering, and 

  

 3 

	 	(B)	a number determined by dividing either 

  

	 	I.	the product of the number of Shares offered under the Rights Offering and the price at which such Shares are offered, 

 or, as the case may be, 
  

	 	II.	the product of the exchange or conversion price per share of such securities offered and the maximum number of Shares for or into which the securities so offered
pursuant to the Rights Offering may be exchanged or converted, 

 by the Current Market Price of the Shares as of
the record date for the Rights Offering; and 
  

	 	(ii)	the denominator of which shall be the aggregate of the number of Shares outstanding on such record date after giving effect to the Rights Offering and including the
number of Shares offered pursuant to the Rights Offering (including shares issuable upon exercise of the rights, warrants or options under the Rights Offering or upon the exercise of the exchange or conversion rights contained in such exchangeable
or convertible securities under the Rights Offering). 

 Any Shares owned by or held for the account of the Company
shall be deemed not to be outstanding for the purpose of any such calculation. To the extent that such Rights Offering is not so made or any such rights, options or warrants are not exercised prior to the expiration thereof, the Exercise Price
shall, then be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or if such expired rights, options or warrants had not been issued. From and after any adjustment of the Exercise Price pursuant to
this Section 6(b), the number of Warrant Shares purchasable pursuant to this Warrant Certificate shall be adjusted contemporaneously with the adjustment of the Exercise Price by multiplying the number of Shares then otherwise purchasable on the
exercise thereof by a fraction, the numerator of which shall be the Exercise Price in effect immediately prior to the adjustment and the denominator of which shall be the Exercise Price resulting from such adjustment. 
  

	 	(c)	Special Distribution. If and whenever during the Exercise Period the Company shall issue or distribute to all or to substantially all the holders of the Shares:

  

	 	(i)	securities of the Company including shares, rights, options or warrants to acquire shares of any class or securities exchangeable for or convertible into or
exchangeable into any such shares or cash, property or assets or evidences of its indebtedness, or 

  

	 	(ii)	any cash, property or other assets, 

 and if such issuance or distribution does not constitute dividends paid in the ordinary course, a Share Reorganization or a Rights Offering (any of such non-excluded events being herein called a “Special Distribution”), the
Exercise Price shall be adjusted immediately after the record date for the Special Distribution so that it shall equal the price determined by multiplying the Exercise Price in effect on such record date by a fraction: 
  

	 	(i)	the numerator of which shall be the difference between: 

  

	 	(A)	the amount obtained by multiplying the number of Shares outstanding on such record date by the Current Market Price of the Shares on such record date, and

  

 4 

	 	(B)	the fair value (as determined by the directors of the Company) to the holders of such Shares of such Special Distribution; and 

  

	 	(ii)	the denominator of which shall be the total number of shares outstanding on such record date multiplied by such Current Market Price of the Shares on such record date.

 Any Common Shares owned by or held for the account of the Company shall be deemed not to be outstanding for the
purpose of any such computation. To the extent that such Special Distribution is not so made or any such rights, options or warrants are not exercised prior to the expiration thereof, the Exercise Price shall then be readjusted to the Exercise Price
which would then be in effect if such record date had not been fixed or if such expired rights, options or warrants had not been issued. From and after any adjustment of the Exercise Price pursuant to this Section 6(c), the number of Warrant
Shares purchasable pursuant to this Warrant Certificate shall be adjusted contemporaneously with the adjustment of the Exercise Price by multiplying the number of Shares then otherwise purchasable on the exercise thereof by a fraction, the numerator
of which shall be the Exercise Price in effect immediately prior to the adjustment and the denominator of which shall be the Exercise Price resulting from such adjustment. 
  

	 	(d)	Capital Reorganization. If and whenever during the Exercise Period there shall be a reclassification or redesignation of Shares at any time outstanding or a
change of the Shares into other shares or into other securities or any other capital reorganization (other than a Share Reorganization), or a consolidation, amalgamation, arrangement or merger of the Company with or into any other corporation or
other entity (other than a consolidation, amalgamation, arrangement or merger which does not result in any reclassification or redesignation of the outstanding Shares or a change of the Shares into other securities), or a transfer of the undertaking
or assets of the Company as an entirety or substantially as an entirety to another corporation or other entity (any of such events being herein called a “Capital Reorganization”), the Holder, where he has not exercised the right of
subscription and purchase under this Warrant Certificate prior to the effective date or record date, as the case may be, of such Capital Reorganization, shall be entitled to receive, and shall accept upon the exercise of such right for the same
aggregate consideration, in lieu of the number of Warrant Shares to which such Holder was theretofore entitled upon such exercise, the kind and aggregate number of shares, other securities or other property which such holder would have been entitled
to receive as a result of such Capital Reorganization if, on the effective date thereof, he had been the registered holder of the number of Shares to which such holder was theretofore entitled to subscribe for and purchase; provided however, that no
such Capital Reorganization shall be carried into effect unless all necessary steps shall have been taken to so entitle the Holder. If determined appropriate by the board of directors of the Company, acting reasonably and in good faith, and subject
to the prior written approval of the principal Canadian stock exchange or over-the-counter market on which the Shares are then listed or quoted for trading, appropriate adjustments shall be made as a result of any such Capital Reorganization in the
application of the provisions set forth in this Section 6 with respect to the rights and interests thereafter of the Holder to the end that the provisions set forth in this Section 6 shall thereafter correspondingly be made applicable as
nearly as may reasonably be possible in relation to any shares, other securities or other property thereafter deliverable upon the exercise of any Warrant. Any such adjustments shall be made by and set forth in terms and conditions supplemental
hereto approved by the board of directors of the Company, acting reasonably and in good faith. 

  

 5 

	 	(e)	If and whenever at any time after the date hereof and prior to the Expiry Time, the Company takes any action affecting its Shares to which the foregoing provisions of
this Section 6, in the opinion of the board of directors of the Company, acting reasonably and in good faith, are not strictly applicable, or if strictly applicable would not fairly adjust the rights of the Holder against dilution in
accordance with the intent and purposes thereof, or would otherwise materially affect the rights of the Holder hereunder, then the Company shall execute and deliver to the Holder an amendment hereto providing for an adjustment in the application of
such provisions so as to adjust such rights as aforesaid in such a manner as the board of directors of the Company may determine to be equitable in the circumstances, acting reasonably and in good faith. The failure of the taking of action by the
board of directors of the Company to so provide for any adjustment on or prior to the effective date of any action or occurrence giving rise to such state of facts will be conclusive evidence, absent manifest error that the board of directors has
determined that it is equitable to make no adjustment in the circumstances. 

  

	7.	The following rules and procedures shall be applicable to the adjustments made pursuant to Section 6: 

  

	 	(a)	The adjustments provided for in Section 6 are cumulative and shall be made successively whenever an event referred to therein shall occur, and shall, in the case
of adjustments to the Exercise Price be computed to the nearest one-tenth of one cent subject to the following paragraphs of this Section 7. 

  

	 	(b)	No adjustment in the Exercise Price shall be required unless such adjustment would result in a change of at least 1% in the prevailing Exercise Price and no adjustment
shall be made in the number of Shares purchasable upon exercise of this Warrant unless it would result in a change of at least one one-hundredth of a Share; provided, however, that any adjustments which, except for the provisions of this
Section 7(b) would otherwise have been required to be made, shall be carried forward and taken into account in any subsequent adjustment. Notwithstanding Section 6 or 7 hereof, no adjustment shall be made which would result in an increase
in the Exercise Price or a decrease in the number of Shares issuable upon the exercise of this Warrant (except in respect of a consolidation of the outstanding Shares). 

  

	 	(c)	No adjustment in the Exercise Price or in the number of Shares purchasable upon exercise of Warrants shall be made in respect of any event described in Section 6,
other than the events referred to in Sections 6(a)(ii) and (iii), if the Holder is entitled to participate in such event on the same terms, mutatis mutandis, as if it had exercised its Warrants prior to or on the effective date or record
date, as the case may be, of such event. The terms of the participation of the Holder in such event shall be subject to the prior written approval, if applicable, of the principal Canadian stock exchange or over-the-counter market on which the
Shares are then listed or quoted for trading. 

  

	 	(d)	No adjustment in the Exercise Price shall be made pursuant to Section 6 in respect of the issue from time to time: 

  

	 	(i)	of Warrant Shares purchasable on exercise of the Warrants represented by this Warrant Certificate; 

  

	 	(ii)	of dividends paid in the ordinary course of Shares to holders of Shares who exercise an option or election to receive substantially equivalent dividends in Shares in
lieu of receiving a cash dividend pursuant to a dividend reinvestment plan or similar plan adopted by the Company in accordance with the requirements of the principal Canadian stock exchange or over-the-counter market on which the Shares are then
listed or quoted for trading and applicable securities laws; or 

  

	 	(iii)	 of Shares pursuant to any stock option, stock option plan, stock purchase plan or benefit plan in force at the date hereof for directors, officers,
employees, advisers or consultants of the Company, as such option or plan is amended or superseded from time to time in

  

 6 

	 	 
accordance with the requirements of the principal Canadian stock exchange or over-the-counter market on which the Shares are then listed or quoted for trading and applicable securities laws, and
such other stock option, stock option plan, stock purchase plan or benefit plan as may be adopted by the Company in accordance with the requirements of the principal Canadian stock exchange or over-the-counter market on which the Shares are then
listed or quoted for trading and applicable securities laws; 

 and any such issue shall be deemed not to be a
Share Reorganization or Capital Reorganization. 
  

	 	(e)	If the Company shall set a record date to determine the holders of the Shares for the purpose of entitling them to receive any dividend or distribution or any
subscription or purchase rights and shall, thereafter and before the distribution to such shareholders of any such dividend, distribution or subscription or purchase rights, legally abandon its plan to pay or deliver such dividend, distribution or
subscription or purchase rights, then no adjustment in the Exercise Price or the number of Shares purchasable upon exercise of any Warrant shall be required by reason of the setting of such record date. 

  

	 	(f)	As a condition precedent to the taking of any action which would require any adjustment in any of the subscription rights pursuant to this Warrant Certificate,
including the Exercise Price and the number or class of shares or other securities which are to be received upon the exercise thereof, the Company shall take any corporate action which may, in the opinion of counsel, be necessary in order that the
Company have unissued and reserved shares in its authorized capital and may validly and legally issue as fully paid and non-assessable all the shares or other securities which the holder of such Warrant Certificate is entitled to receive on the full
exercise thereof in accordance with the provisions hereof. 

  

	 	(g)	For the purposes of this Warrant Certificate, “Current Market Price” of a Share at any date shall be calculated as the price per Share equal to the weighted
average price at which the Shares have traded in the principal Canadian stock exchange or, if the Shares are not listed, the over-the-counter market, on which the Shares are then listed or posted for trading during the 20 consecutive trading days
(on each of which at least 500 Shares are traded in board lots) ending not more than five trading days immediately prior to such date as reported by such market or exchange in which the Shares are then trading or quoted. If the Shares are not then
traded in the over-the-counter market or on a recognized Canadian stock exchange, the Current Market Price of the Shares shall be the fair market value of the Shares as determined in good faith by the board of directors of the Company after
consultation with a nationally or internationally recognized and independent investment dealer, investment banker or firm of chartered accountants. 

  

	 	(h)	In the absence of a resolution of the board of directors of the Company fixing a record date for any dividend or distribution referred to in Section 6(a)(i) or any
Rights Offering or Special Distribution, the Company shall be deemed to have fixed as the record date therefor the date on which such dividend or distribution, Rights Offering or Special Distribution is effected. 

  

	 	(i)	Any question that at any time or from time to time arises with respect to the amount of any adjustment to the Exercise Price or other adjustments pursuant to
Section 6 shall be conclusively determined by a firm of independent chartered accountants (who may be the Company’s auditors) and shall be binding upon the Company and the Holder, absent manifest error. Notwithstanding the foregoing, such
determination shall be subject to the prior written approval of the principal Canadian stock exchange or over-the-counter market on which the Shares are then listed or quoted for trading. In the event that any such determination is made, the Company
shall notify the Holder in the manner contemplated in Section 19 describing such determination. 

  

 7 

	8.	On the happening of each and every such event set out in Section 6, the applicable provisions of this Warrant Certificate, including the Exercise Price, shall,
ipso facto, be deemed to be amended accordingly and the Company shall take all necessary action so as to comply with such provisions as so amended. 

  

	9.	In any case in which Section 6 shall require that an adjustment shall be effective immediately after a record date for an event referred to herein, the Company may
defer, until the occurrence of such an event: 

  

	 	(a)	issuing to the holder of any Warrant exercised after such record date and before the occurrence of such event, the additional Shares issuable upon such exercise by
reason of the adjustment required by such event, and 

  

	 	(b)	delivering to such holder any distributions declared with respect to such additional Shares after such Exercise Date and before such event; 

 provided, however, that the Company shall deliver or cause to be delivered to such holder, an appropriate instrument evidencing such
holder’s right, upon the occurrence of the event requiring the adjustment, to an adjustment in the Exercise Price and/or the number of Shares purchasable on the exercise of any Warrant and to such distributions declared with respect to any
additional Shares issuable on the exercise of any Warrant. 
  

	10.	At least ten Business Days prior to the effective date or record date, as the case may be, of any event which requires or might require adjustment in any of the
subscription rights pursuant to this Warrant Certificate, including the Exercise Price and the number of Shares which are purchasable upon the exercise thereof, or such longer period of notice as the Company shall be required to provide holders of
Shares in respect of any such event, the Company shall notify the Holder of the particulars of such event and, if determinable, the required adjustment and the computation of such adjustment. In case any adjustment for which such notice has been
given is not then determinable, the Company shall promptly after such adjustment is determinable notify the Holder of the adjustment and the computation of such adjustment. 

  

	11.	The Company shall maintain a register of holders in which shall be entered the names and addresses of the holders of the Warrants and of the number of Warrants held by
them. Such register shall be open at all reasonable times for inspection by the Holder. The Company shall notify the Holder forthwith of any change of address of the principal office of the Company. 

  

	12.	The Company shall not be required to issue fractional Warrant Shares in satisfaction of its obligations hereunder. If any fractional interest in a Warrant Share would,
except for the provisions of this Section 12, be deliverable upon the exercise of a Warrant, the Company shall in lieu of delivering the fractional Warrant Shares therefor satisfy the right to receive such fractional interest by payment to the
holder of such Warrant of an amount in cash equal (computed in the case of a fraction of a cent to the next lower cent) to the value of the right to acquire such fractional interest on the basis of the Current Market Price at the Exercise Date.

  

	13.	Subject as herein provided, all or any of the rights conferred upon the Holder by the terms hereof may be enforced by the Holder by appropriate legal proceedings.

  

	14.	The registered Holder of this Warrant Certificate may at any time up to and including the Expiry Time, upon the surrender hereof to the Company at its principal office,
exchange this Warrant Certificate for one or more Warrant Certificates entitling the Holder to subscribe in the aggregate for the same number of Shares as is expressed in this Warrant Certificate. Any Warrant Certificate tendered for exchange shall
be surrendered to the Company and cancelled. 

  

	15.	If this Warrant Certificate becomes stolen, lost, mutilated or destroyed, the Company shall, on such terms as it may in its discretion acting reasonably impose, issue
and deliver to the Holder a new Warrant Certificate of like denomination, tenor and date as the Warrant Certificate so stolen, lost, mutilated or destroyed. 

  

 8 

	16.	Nothing contained herein shall confer any right upon the Holder hereof or any other person to subscribe for or purchase any Shares of the Company at any time subsequent
to the Expiry Time. After the Expiry Time this Warrant Certificate and all rights hereunder shall be void and of no value. 

  

	17.	Except as expressly set out herein, the holding of this Warrant Certificate or the Warrants represented hereby shall not constitute a Holder hereof a holder of Shares
nor entitle it to any right of interest in respect thereof. 

  

	18.	Unless herein otherwise expressly provided, any notice to be given hereunder to the Holder shall be deemed to be validly given if such notice is given by personal
delivery or registered mail to the attention of the Holder at its registered address recorded in the registers maintained by the Company. Any notice so given shall be deemed to be validly given, if delivered personally, on the day of delivery and if
sent by post or other means, on the fifth Business Day next following the sending thereof. In determining under any provision hereof the date when notice of any event must be given, the date of giving notice shall be included and the date of the
event shall be excluded. 

  

	19.	Time is of the essence hereof. 

  

	20.	This Warrant Certificate is binding upon the Company and its successors and assigns, provided that it shall not be assigned by the Company without the prior consent of
the Holder. 

  

	21.	This Warrant Certificate and the Warrants granted hereunder shall be governed by and be interpreted in accordance with the laws of the Province of British Columbia and
the federal laws of Canada applicable therein. The parties hereto irrevocably attorn to the jurisdiction of the courts of the Province of British Columbia. 

 IN WITNESS WHEREOF this Warrant Certificate has been executed on behalf of Med BioGene Inc. as of December 24, 2009. 
  

			
	MED BIOGENE INC.
		
	 By:
	 	  

		 	Authorized Signing Officer

  

 9 

 SUBSCRIPTION NOTICE 
  

			
	TO:    	  	MED BIOGENE INC.
		  	#300 - 2386 East Mall
		  	Gerald McGavin Building Vancouver, British Columbia
		  	V6T 1Z3

 Attention: Chief Financial Officer 
 Terms used herein but not otherwise defined have the meanings ascribed thereto in the attached Warrant Certificate. 
 The Holder of the attached Warrant Certificate, hereby: 
  

	 	(a)	subscribes for
                             Warrant Shares at a price per of Cdn.$0.18 per Share (or such adjusted
price which may be in effect under the provisions of the Warrant Certificate) and in payment of the exercise price encloses a certified cheque, bank draft or money order in lawful money of Canada payable to the order of Med BioGene Inc. or its
successor corporation; and 

  

	 	(b)	delivers herewith the above-mentioned Warrant Certificate entitling the undersigned to subscribe for the above-mentioned number of Warrant Shares,

 in each case in accordance with the terms and conditions set out in the attached Warrant Certificate. 
 The undersigned hereby irrevocably directs that the said Warrant Shares be registered and delivered as follows: 
  

											
	 Name(s) in Full
	  	 Address(es) *
	  	 Number of Warrant
Shares

		  		  	
		  		  	
		  		  	
		  		  	
		  		  	 Total Number of Warrant
Shares

		  		  	

  

									
	 Total Purchase
Price

					
		  	X	  	$0.18	  	=	  	$
	  
	  		  	  
	  		  	  

					
	 No. Warrant
 Shares
	  		  	 Price Per
 Share
	  		  	 Total Purchase
 Price

  

	*	Certificates representing Warrant Shares will not be registered or delivered to an address in the United States unless Box B below is checked. 

 In connection with this exercise of the Warrant, the Holder encloses cash, a bank draft or a certified
cheque payable to the Company in the amount described in the table above as full payment for the Warrant Shares to be acquired hereby. 
 The
Holder represents, warrants and certifies as follows (one (only) of the following must be checked): 
  

						
	 A.
	 	 ̈	 	  	He, she or it is: (i) at the time of exercise of the Warrant is not in the United States; (ii) is not a “U.S. person”, as defined in Regulation S under the
United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and is not exercising this Warrant on behalf of a “U.S. person” or a person in the United States; and (iii) did not execute or deliver this
Subscription Notice in the United States.
			
	 B.
	 	 ̈	 	  	He, she or it is tendering with this Subscription Notice an opinion of counsel reasonably satisfactory to the Company to the effect that the exercise of the Warrant made is
pursuant to an effective registration statement under the U.S. Securities Act or that an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available.

 The Holder understands that unless Box A above is checked or the exercise is made pursuant to an
effective registration statement under the U.S. Securities Act, the certificate representing the Warrant Shares will bear a legend to the following effect: 
 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE
OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE ISSUER THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED ONLY: (A) TO THE ISSUER, (B) OUTSIDE THE UNITED STATES IN AN
OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (C) INSIDE THE UNITED STATES IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER
THE U.S. SECURITIES ACT OR ANY APPLICABLE UNITED STATES FEDERAL OR STATE SECURITIES LAWS, AFTER PROVIDING AN OPINION OF COUNSEL OF RECOGNIZED STANDING REASONABLY SATISFACTORY TO THE ISSUER TO THAT EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT
CONSTITUTE “GOOD DELIVERY” IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.” 
 The Holder further understands that if
the Warrant is exercised at a time when the Company is not a “foreign issuer” (as defined in Regulation S under the U.S. Securities Act) and Box A above is checked, the Holder agrees and understands that the Warrant Shares may be
transferred without registration only to the Company, outside the United States in compliance with Rule 904 under the U.S. Securities Act, or pursuant to an exemption from registration, and that hedging transactions with regard to the Warrant Shares
may not be conducted unless in compliance with the U.S. Securities Act, and the certificate representing the Warrant Shares will bear a legend to such effect. 
 DATED this    of         ,         . 
  

					
	  
	 		  	  

	Signature Guaranteed by:	 		  	Signature of Holder*
			
		 		  	  

		 		  	Name of Holder
			
		 		  	  

		 		  	  
  

		 		  	Address of Holder (include postal code or zip code)

  

	*	This signature must correspond exactly with the name appearing on the Warrant Certificate. 

  

	 ̈	Please check box if the Warrant Share certificates are to be delivered at the office where this Subscription Notice is surrendered, failing which the certificates will
be mailed to the addresses noted above. 

  

 2 

 EXERCISE OF THE WARRANT 
 Instructions: 
  

	1.	The Holder may exercise his, her or its right to receive Warrant Shares by completing this form and surrendering this form and the Warrant Certificate representing the
Warrants being exercised, along with and a certified cheque, money order or bank draft payable to the Company for the aggregate Exercise Price of all Warrants being exercised, to the Company at its principal office in Vancouver, British Columbia.

  

	2.	If this Subscription Notice indicates that Warrant Shares are to be issued to a person or persons other than the Holder, the signature of such other person or persons
must be guaranteed by an authorized officer of a chartered bank, trust company or medallion guaranteed by a member of a recognized medallion guarantee program. 

  

	3.	If this Subscription Notice is signed by a trustee, executor, administrator, curator, guardian, attorney, officer of a company or any person acting in a judiciary or
representative capacity, the certificate must be accompanied by evidence of authority to sign satisfactory to the Company. 

  

 3Form of Warrant to be granted to the Underwriter

 Exhibit 4.8 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL
TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF SUCH SECURITIES BY ANY PERSON FOR A PERIOD OF SIX (6) MONTHS IMMEDIATELY FOLLOWING THE DATE OF EFFECTIVENESS OF THE COMPANY’S REGISTRATION STATEMENT NO.:
333-                     AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, EXCEPT IN ACCORDANCE WITH THE TERMS HEREOF. 
 MED BIOGENE INC. 
 UNDERWRITER’S WARRANT 
 [            ]
Common Shares 
                     , 2010 
 This UNDERWRITER’S WARRANT (this “Warrant”) of Med BioGene Inc., a company amalgamated under the Business Corporations Act (British Columbia) (the
“Company”), is being issued pursuant to that certain Underwriting Agreement, dated as of                     , 2010 (the
“Underwriting Agreement”), by and among the Company and Rodman & Renshaw, LLC, (the “Underwriter”) relating to a firm commitment public offering (the “Offering”) of
             common shares of the Company (the “Common Shares”) underwritten by the Underwriter named in the Underwriting Agreement. 
 FOR VALUE RECEIVED, the Company hereby grants to
                     and its permitted successors and assigns (collectively, the “Holder”), the right to purchase from the
Company up to                      (            ) Common Shares [5% of Firm Shares] (such
shares underlying this Warrant, the “Warrant Shares”), at a per share purchase price equal to $             [125% of public offering price of Firm Shares] (the
“Exercise Price”), subject to the terms, conditions and adjustments set forth below in this Warrant. Upon acceptance of this Warrant, Holder agrees to be bound by the terms and conditions hereof. 
 1. Date of Warrant Exercise. This Warrant shall become exercisable on the date that is one (1) year from the Base Date (the
“Exercise Date”). As used in this Warrant, the term “Base Date” shall mean                     , 2010.

 2. Expiration of Warrant. This Warrant shall expire on the five (5) year anniversary of the Base Date (the
“Expiration Date”). 
 3. Exercise of Warrant. This Warrant shall be exercisable pursuant to the
terms of this Section 3. 
 3.1 Manner of Exercise. 
 (a) This Warrant may only be exercised by the Holder hereof on or after the Exercise Date and on or prior to the Expiration Date, in
accordance with the terms and conditions hereof, in whole or in part (but not as to fractional shares) with respect to any portion of this Warrant, during the Company’s normal business hours on any day other than a Saturday or a Sunday or a day
on which commercial banking institutions in Vancouver, British Columbia are authorized by law to be closed (a “Business Day”), by surrender of this Warrant to the Company at its office maintained pursuant to Section 11.2(a)
hereof, accompanied by a written exercise notice in the form attached as Exhibit A to this

 
Warrant (or a reasonable facsimile thereof) duly executed by the Holder, together with the payment of the aggregate Exercise Price for the number of Warrant Shares purchased upon exercise of this
Warrant. Upon surrender of this Warrant, the Company shall cancel this Warrant document and shall, in the event of partial exercise, replace it with a new Warrant document in accordance with Section 3.3. 
 (b) Except as provided for in Section 3.1(c) below, each exercise of this Warrant must be accompanied by payment in full of the
aggregate Exercise Price in cash by certified check, official bank check or wire transfer in immediately available funds for the number of Warrant Shares being purchased by the Holder upon such exercise. 
 (c) Subject to any limitation pursuant to applicable Canadian exchange rules or policies, the aggregate Exercise Price for the number of
Warrant Shares being purchased may also, in the sole discretion of the Holder, be paid in full or in part on a “cashless basis” at the election of the Holder: 
 (i) in the form of Common Shares owned by the Holder (based on the Fair Market Value (as defined below) of such Common Shares on the date of exercise); 
 (ii) in the form of Warrant Shares withheld by the Company from the Warrant Shares otherwise to be received upon exercise of this Warrant
having an aggregate Fair Market Value on the date of exercise equal to the aggregate Exercise Price of the Warrant Shares being purchased by the Holder; or 
 (iii) by a combination of the foregoing, provided that the combined value of all cash and the Fair Market Value of any shares surrendered to the Company is at least equal to the aggregate Exercise Price
for the number of Warrant Shares being purchased by the Holder. 
 For purposes of this Warrant, the term “Fair Market
Value” means with respect to a particular date, the average closing price of the Common Shares for the five (5) trading days immediately preceding the applicable exercise date herein as officially reported by the principal securities
exchange on which the Common Stock is then listed or admitted to trading, or, if the Common Stock is not listed or admitted to trading on any securities exchange as determined in good faith by resolution of the Board of Directors of the Company,
based on the best information available to it. 
 For purposes of illustration of a cashless exercise of this Warrant under
Section 3.1(c)(ii) (or for a portion thereof for which cashless exercise treatment is requested as contemplated by Section 3.1(c)(iii) hereof), the calculation of such exercise shall be as follows: 
 X = Y * (A-B)/A 
 where: 
  

	 	X =	the number of Warrant Shares to be issued to the Holder (rounded to the nearest whole share). 

  

	 	Y =	the number of Warrant Shares with respect to which this Warrant is being exercised. 

  

	 	A =	the Fair Market Value of the Common Shares. 

  

	 	B =	the Exercise Price. 

  

 2 

 (d) For purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is intended, understood,
and acknowledged that the Common Shares issuable upon exercise of this Warrant in a cashless exercise transaction as described in Section 3.1(c) above shall be deemed to have been acquired at the time this Warrant was issued. Moreover, it
is intended, understood, and acknowledged that the holding period for the Common Shares issuable upon exercise of this Warrant in a cashless exercise transaction as described in Section 3.1(c) above shall be deemed to have commenced on the date
this Warrant was issued. 
 3.2 When Exercise Effective. Each exercise of this Warrant shall be deemed to have been
effected immediately prior to the close of business on the Business Day on which this Warrant shall have been duly surrendered to the Company as provided in Sections 3.1 and 12 hereof, and, at such time, the Holder in whose name any certificate or
certificates for Warrant Shares shall be issuable upon exercise as provided in Section 3.3 hereof shall be deemed to have become the holder or holders of record thereof of the number of Warrant Shares purchased upon exercise of this Warrant.

 3.3 Delivery of Common Share Certificates and New Warrant. As soon as reasonably practicable after each exercise of
this Warrant, in whole or in part, and in any event within five (5) Business Days thereafter, the Company, at its expense (including the payment by it of any applicable issue taxes), will cause to be issued in the name of and delivered to the
Holder hereof or, subject to Sections 9 and 10 hereof, as the Holder (upon payment by the Holder of any applicable transfer taxes) may direct: 
 (a) a certificate or certificates (with an appropriate restrictive legend in accordance with Section 10.1 hereof, as applicable) for the number of duly authorized, validly issued, fully paid and
nonassessable Warrant Shares to which the Holder shall be entitled upon exercise; and 
 (b) in case exercise is in part only, a
new Warrant document of like tenor, dated the date hereof, for the remaining number of Warrant Shares issuable upon exercise of this Warrant after giving effect to the partial exercise of this Warrant (including the delivery of any Warrant Shares as
payment of the Exercise Price for such partial exercise of this Warrant). 
 4. Registration Rights. 
 4.1 Demand Registration. 
 4.1.1 Grant of Right. The Company, upon written demand made at any time beginning twelve (12) months from the Base Date and for a period of three (3) years thereafter (a “Demand
Notice”) of the Holder(s) of at least 25% of the Warrants and/or the Warrant Shares (the “Demanding Holders”), agrees to register, on one occasion, all or any portion of the Warrant Shares (collectively the
“Registrable Securities”). On such occasion, the Company will file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the Registrable Securities within sixty (60) days
after receipt of a Demand Notice and use its Reasonable Best Efforts (as defined in Section 15 hereof) to have the registration statement declared effective promptly thereafter, subject to compliance with review by the SEC; provided,
however, that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section 4.2 hereof
and either: (i) the Holder has elected to participate in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary offering of securities of the Company, until the
offering covered by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when:
(A) a registration statement with respect to the sale of such securities shall have become

  

 3 

 
effective under the Securities Act of 1933, as amended (the “Securities Act”) and such securities shall have been sold, transferred, disposed of or exchanged in accordance with
such registration statement; (B) such securities shall have been otherwise transferred, new certificates for them not bearing a legend restricting further transfer shall have been delivered by the Company and subsequent public distribution of
them shall not require registration under the Securities Act; or (C) such securities shall have ceased to be outstanding. In addition, the term Registrable Securities shall not include any securities held by any Holder if such securities are
then freely tradeable under Rule 144 without restriction in the opinion of counsel to the Company. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered Holders of the
Warrants and/or the Registrable Securities within ten (10) days from the date of the receipt of any such Demand Notice.
 4.1.2 Terms. The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1, but the Holders shall pay any and all underwriting commissions and the
expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. Subject to Section 4.1.1, the Company agrees to use its Reasonable Best Efforts to cause the filing required
herein to become effective promptly and to qualify or register the Registrable Securities in such States as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required to register the
Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit to general service of process in such State, or (ii) the principal
shareholders of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted under Section 4.1.1 to remain effective for a
period of at least twelve (12) consecutive months from the date that the Holders of the Registrable Securities covered by such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the
prospectuses provided by the Company to sell the shares covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used
due to a material misstatement or omission.
 4.2 “Piggy-Back” Registration. 
 4.2.1 Grant of Right. In addition to the demand right of registration, described in Section 4.1 hereof the Holder shall
have the right to include the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to
Form S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a
limitation on the number of Common Shares which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the
Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of
Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall
not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion
with the Registrable Securities. 
 4.2.2 Terms. The Company shall bear all fees and expenses attendant to
registering the Registrable Securities pursuant to Section 4.2.1 hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale
of the Registrable Securities. In the event of such a proposed registration, the

  

 4 

 
Company shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date of filing of such registration
statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall
exercise the “piggy-back” rights provided for herein by giving written notice, within ten (10) days of the receipt of the Company’s notice of its intention to file a registration statement. 
 4.3 General Terms. 
 4.3.1 Indemnification. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and each person, if any, who controls
such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and
with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriter contained in Section              of the Underwriting Agreement between the
Underwriter and the Company, dated as of                     , 2010. The Holder(s) of the Registrable Securities to be sold pursuant to such
registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably
incurred in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their
successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the provisions contained in Section              of
the Underwriting Agreement pursuant to which the Underwriter has agreed to indemnify the Company.
 4.3.2 Exercise of
Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof. 
 4.3.3 Documents Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings
and to each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company, dated the effective date of such registration statement (and, if such
registration includes an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold comfort” letter dated the effective date of such registration
statement (and, if such registration includes an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent public accountants who have issued a report on the Company’s
financial statements included in such registration statement, in each case covering substantially the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants’ letter,
with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer’s counsel and in accountants’ letters delivered to underwriters in underwritten public offerings of securities.
The Company shall also deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence between the SEC and the Company,
its counsel or auditors and all memoranda relating to discussions with the SEC or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to
information contained in or omitted from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties and

  

 5 

 
opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably
request. 
 4.3.4 Underwriting Agreement. The Company shall enter into an underwriting agreement with the managing
underwriter(s), if any, selected by any Holders whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably satisfactory to the Company. Such agreement shall be reasonably
satisfactory in form and substance to the Company, each Holder and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily contained in agreements of that
type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties and
covenants of the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or agreements with the Company or the
underwriters except as they may relate to such Holders, their Common Shares and their intended methods of distribution.
 4.3.5 Documents to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company a completed and executed questionnaire provided by the Company requesting
information customarily sought of selling security holders. 
 4.3.6 Damages. Should the registration or the
effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be
entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the
necessity of posting bond or other security. 
 5. Certain Adjustments. For so long as this Warrant is
outstanding: 
 5.1 Mergers or Consolidations. If at any time after the date hereof there shall be a capital
reorganization (other than a combination or subdivision of Common Shares otherwise provided for herein) resulting in a reclassification to or change in the terms of securities issuable upon exercise of this Warrant (a
“Reorganization”), or an amalgamation, merger or consolidation of the Company with another corporation, association, partnership, organization, business, individual, government or political subdivision thereof or a governmental
agency (a “Person” or the “Persons”) (other than a merger with another Person in which the Company is a continuing corporation and which does not result in any reclassification or change in the terms of securities
issuable upon exercise of this Warrant or a merger effected exclusively for the purpose of changing the domicile of the Company) (a “Merger”), then, as a part of such Reorganization or Merger, lawful provision and adjustment shall
be made so that the Holder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares of stock or any other equity or debt securities or property receivable upon such Reorganization or Merger by a holder of the
number of Common Shares which might have been purchased upon exercise of this Warrant immediately prior to such Reorganization or Merger. In any such case, appropriate adjustment shall be made in the application of the provisions of this
Warrant with respect to the rights and interests of the Holder after the Reorganization or Merger to the end that the provisions of this Warrant (including adjustment of the Exercise Price then in effect and the number of Warrant Shares) shall be
applicable after that event, as near as reasonably may be, in relation to any shares of stock, securities, property or other assets thereafter deliverable upon exercise of this Warrant. The provisions of this Section 4.1 shall similarly
apply to successive Reorganizations and/or Mergers. 
  

 6 

 5.2 Splits and Subdivisions; Dividends. In the event the Company should at
any time or from time to time effectuate a split or subdivision of the outstanding Common Shares or pay a dividend in or make a distribution payable in additional Common Shares or Common Shares Equivalents without payment of any consideration by
such holder for the additional Common Shares or Common Share Equivalents (including the additional Common Shares issuable upon conversion or exercise thereof), then, as of the applicable record date (or the date of such distribution, split or
subdivision if no record date is fixed), the per share Exercise Price shall be appropriately decreased and the number of Warrant Shares shall be appropriately increased in proportion to such increase (or potential increase) of outstanding shares;
provided, however, that no adjustment shall be made in the event the split, subdivision, dividend or distribution is not effectuated. 
 5.3 Combination of Shares. If the number of Common Shares outstanding at any time after the date hereof is decreased by a combination of the outstanding Common Shares, the per share
Exercise Price shall be appropriately increased and the number of shares of Warrant Shares shall be appropriately decreased in proportion to such decrease in outstanding Common Shares. 
 5.4 Adjustments for Other Distributions. In the event the Company shall declare a distribution payable in securities of
other Persons, evidences of indebtedness issued by the Company or other Persons, assets (excluding cash dividends or distributions to the holders of Common Stock paid out of current or retained earnings and declared by the Company’s board of
directors) or options or rights not referred to in Sections 5.2, 5.3 or 5.4, then, in each such case for the purpose of this Section 5.5, upon exercise of this Warrant, the Holder shall be entitled to a proportionate share of any such
distribution as though the Holder was the actual record holder of the number of Warrant Shares as of the record date fixed for the determination of the holders of Common Shares of the Company entitled to receive such distribution. 
 6. No Impairment. The Company will not, by amendment of its articles or through any consolidation, merger, reorganization,
transfer of assets, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of
all of the terms and in the taking of all actions necessary or appropriate in order to protect the rights of the Holder against impairment. 
 7. Chief Financial Officer’s Report as to Adjustments. With respect to each adjustment pursuant to Section 5 of this Warrant, the Company, at its expense, will promptly compute
the adjustment or re-adjustment in accordance with the terms of this Warrant and cause its Chief Financial Officer to certify the computation (other than any computation of the fair value of property of the Company, as the case may be) and prepare a
report setting forth, in reasonable detail, the event requiring the adjustment or re-adjustment and the amount of such adjustment or re-adjustment, the method of calculation thereof and the facts upon which the adjustment or re-adjustment is based,
and the Exercise Price and the number of Warrant Shares or other securities purchasable hereunder after giving effect to such adjustment or re-adjustment, which report shall be mailed by first class mail, postage prepaid to the Holder. The
Company will also keep copies of all reports at its office maintained pursuant to Section 11.2(a) hereof and will cause them to be available for inspection at the office during normal business hours upon reasonable notice by the Holder or any
prospective purchaser of the Warrant designated by the Holder thereof. 
 8. Reservation of Shares. The Company
shall, solely for the purpose of effecting the exercise of this Warrant, at all times during the term of this Warrant, reserve and keep available out of its authorized Common Shares, free from all taxes, liens and charges with respect to the issue
thereof and not subject to preemptive rights or other similar rights of shareholders of the Company, such number of its Common Shares as shall from time to time be sufficient to effect in full the exercise of this Warrant. If at

  

 7 

 
any time the number of authorized but unissued Common Shares shall not be sufficient to effect in full the exercise of this Warrant, in addition to such other remedies as shall be available to
Holder, the Company will promptly take such corporate action as may, in the opinion of its counsel, be necessary to increase the number of authorized but unissued Common Shares to such number of shares as shall be sufficient for such purposes,
including without limitation, using its Reasonable Best Efforts to obtain the requisite shareholder approval necessary to increase the number of authorized Common Shares. The Company hereby represents and warrants that all Common Shares
issuable upon exercise of this Warrant shall be duly authorized and, when issued and paid for upon exercise in accordance with the terms hereof, shall be validly issued, fully paid and nonassessable. 
 9. Listing. The Company shall secure the listing of the Common Shares underlying this Warrant upon each national securities
exchange or automated quotation system upon which Common Shares are then listed or quoted (subject to official notice of issuance) and, prior to the Company effecting any merger, amalgamation, capital stock exchange, asset acquisition or other
business combination transaction that is approved by the board of directors of the Company, the Company shall its Reasonable Best Efforts to maintain such listing for a period of three (3) years after the date hereof. The Company shall at
all times while listed comply in all material respects with the Company’s reporting, filing and other obligations under the by-laws or rules of the The NASDAQ Stock Market (or such other national securities exchange or market on which the
Common Shares may then be listed, as applicable). 
 10. Restrictions on Transfer. 
 10.1 Restrictive Legends. This Warrant and each Warrant issued upon transfer or in substitution for this Warrant pursuant
to Section 11 hereof, each certificate for Common Shares issued upon the exercise of the Warrant and each certificate issued upon the transfer of any such Common Shares shall be transferable only upon satisfaction of the conditions specified in
this Section 10. Each of the foregoing securities shall be stamped or otherwise imprinted with a legend as follows unless such securities have been registered under the Securities Act: 
 “The common shares represented by this certificate have not been registered under the Securities Act of 1933, as amended (the
“Act”) or applicable state law. The common shares may not be offered for sale, sold or otherwise transferred, except pursuant to an effective registration statement under the Act or pursuant to an exemption from registration under the Act
and applicable state law in the opinion of counsel.” 
 10.2 Notice of Proposed Transfer. Prior to any
transfer of any securities which are not registered under an effective registration statement under the Securities Act (“Restricted Securities”), which transfer may only occur if there is an exemption from the registration
provisions of the Securities Act and all other applicable securities laws, the Holder will give written notice to the Company of the Holder’s intention to effect a transfer (and shall describe the manner and circumstances of the proposed
transfer). The following provisions shall apply to any proposed transfer of Restricted Securities: 
 (i) If in the
opinion of counsel for the Holder reasonably satisfactory to the Company the proposed transfer may be effected without registration of the Restricted Securities under the Securities Act (which opinion shall state in detail the basis of the legal
conclusions reached therein), the Holder shall thereupon be entitled to transfer the Restricted Securities in accordance with the terms of the notice delivered by the Holder to the Company. Each certificate representing the Restricted
Securities

  

 8 

 
issued upon or in connection with any transfer shall bear the restrictive legend required by Section 10.1 hereof. 
 (ii) If the opinion called for in (i) above is not delivered, the Holder shall not be entitled to transfer the Restricted
Securities until either: (x) receipt by the Company of a further notice from such Holder pursuant to the foregoing provisions of this Section 10.2 and fulfillment of the provisions of clause (i) above, or (y) such Restricted
Securities have been effectively registered under the Securities Act. 
 10.3 Certain Other Transfer
Restrictions. Notwithstanding any other provision of this Section 10: (i) prior to the Exercise Date, this Warrant or the Restricted Securities thereunder may only be transferred or assigned to the persons permitted under FINRA
Rule 5110(g); and (ii) no opinion of counsel shall be necessary for a transfer of Restricted Securities by the Holder thereof to any Person employed by or owning equity in the Holder, if the transferee agrees in writing to be subject to the
terms hereof to the same extent as if the transferee were the original purchaser hereof and such transfer is permitted under applicable securities law. 
 10.4 Termination of Restrictions. Except as set forth in Section 10.3 hereof, the restrictions imposed by this Section 10 upon the transferability of Restricted Securities shall
cease and terminate as to any particular Restricted Securities: (a) which shall have been effectively registered under the Securities Act, or (b) when, in the opinions of both counsel for the Holder thereof and counsel for the Company,
such restrictions are no longer required in order to insure compliance with the Securities Act. Whenever such restrictions shall cease and terminate as to any Restricted Securities, the Holder thereof shall be entitled to receive from the
Company, without expense (other than applicable transfer taxes, if any), new securities of like tenor not bearing the applicable legend required by Section 10.1 hereof. 
 11. Ownership, Transfer, Sale and Substitution of Warrant. 
 11.1 Ownership of Warrant. The Company may treat any Person in whose name this Warrant is registered in the Warrant
Register maintained pursuant to Section 11.2(b) hereof as the owner and holder thereof for all purposes, notwithstanding any notice to the contrary, except that, if and when any Warrant is properly assigned in blank, the Company may (but shall
not be obligated to) treat the bearer thereof as the owner of such Warrant for all purposes, notwithstanding any notice to the contrary. Subject to Sections 10 and 11 hereof, this Warrant, if properly assigned, may be exercised by a new holder
without a new Warrant first having been issued. 
 11.2 Office; Exchange of Warrant. 
 (a) The Company will maintain its principal office at the location identified in the prospectus relating to the Offering or at such
other offices as set forth in the Company’s most current filing (as of the date notice is to be given) under the Exchange Act or as the Company otherwise notifies the Holder. 
 (b) The Company shall cause to be kept at its office maintained pursuant to Section 11.2(a) hereof a Warrant Register for the
registration and transfer of the Warrant. The name and address of the holder of the Warrant, the transfers thereof and the name and address of the transferee of the Warrant shall be registered in such Warrant Register. The Person in whose
name the Warrant shall be so registered shall be deemed and treated as the owner and holder thereof for all purposes of this Warrant, and the Company shall not be affected by any notice or knowledge to the contrary. 
  

 9 

 (c) Upon the surrender of this Warrant together with the assignment in the form
attached as Exhibit B to this Warrant (or a reasonable facsimile thereof) duly executed by the Holder, for registration of transfer or for exchange at the office of the Company maintained pursuant to Section 11.2(a) hereof, the Company
at its expense will (subject to compliance with Section 10 hereof, if applicable) execute and deliver to or upon the order of the Holder thereof a new Warrant of like tenor, in the name of such Holder or as such Holder (upon payment by such
Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face thereof for the number of Common Shares called for on the face of the Warrant so surrendered (after giving effect to any previous adjustment(s) to the number
of Warrant Shares). 
 11.3 Replacement of Warrant. Upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, upon delivery of indemnity reasonably satisfactory to the Company in form and amount or, in the case of
any mutilation, upon surrender of this Warrant for cancellation at the office of the Company maintained pursuant to Section 11.2(a) hereof, the Company, at its expense, will execute and deliver, in lieu thereof, a new Warrant of like tenor and
dated the date hereof. 
 11.4 Opinions. In connection with the sale of the Warrant Shares by Holder, the Company agrees to
cooperate with the Holder, and at the Company’s expense, have its counsel provide any legal opinions required to remove the restrictive legends from the Warrant Shares in connection with a sale, transfer or legend removal request of Holder.

 12. No Rights or Liabilities as Stockholder. No Holder shall be entitled to vote or receive dividends or be
deemed the holder of any shares of Common Stock or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any
of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any
recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, amalgamation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until
the Warrant shall have been exercised and the Common Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. The Holder will not be entitled to share in the assets of the Company in the event of a
liquidation, dissolution or the winding up of the Company. 
 13. Notices. Any notice or other communication in
connection with this Warrant shall be given in writing and directed to the parties hereto as follows: (a) if to the Holder, c/o
                     [—name and fax and/or email address] or (b) if to the Company, to the attention of its Chief Executive Officer at its
office maintained pursuant to Section 11.2(a) hereof; provided that the exercise of the Warrant shall also be effected in the manner provided in Section 3 hereof. Notices shall be deemed properly delivered and received when delivered
to the notice party (i) if personally delivered, upon receipt or refusal to accept delivery, (ii) if sent via facsimile, upon mechanical confirmation of successful transmission thereof generated by the sending telecopy machine,
(iii) if sent by a commercial overnight courier for delivery on the next Business Day, on the first Business Day after deposit with such courier service, or (iv) if sent by registered or certified mail, five (5) Business Days after
deposit thereof in the U.S. mail. 
 14. Payment of Taxes. The Company will pay all documentary stamp taxes
attributable to the issuance of Common Shares underlying this Warrant upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the
transfer or registration of this Warrant or any certificate for Common Shares

  

 10 

 
underlying this Warrant in a name other that of the Holder. The Holder is responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or
receiving Common Shares underlying this Warrant upon exercise hereof. 
 15. Miscellaneous. This Warrant and
any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought. This Warrant shall be construed and
enforced in accordance with and governed by the laws of the State of New York. The section headings in this Warrant are for purposes of convenience only and shall not constitute a part hereof. When used herein, the term “Reasonable
Best Efforts” means, with respect to the applicable obligation of the Company, reasonable best efforts for similarly situated, publicly-traded companies. 
 [Remainder of page intentionally left blank] 
  

 11 

 IN WITNESS WHEREOF, the Company has caused this Underwriter’s Warrant to be duly
executed as of the date first above written. 
  

			
	MED BIOGENE INC.
		
	By:	 	 
		 	Name: Erinn B. Broshko
		 	Title: Chief Executive Officer

  

 12 

 EXHIBIT A 
 FORM OF EXERCISE NOTICE 
 [To be executed only upon exercise of Warrant]

 To MED BIOGENE INC.: 
 The undersigned registered holder of the within Warrant hereby irrevocably exercises the Warrant pursuant to Section 3.1 of the Warrant with respect to
                     Warrant Shares, at an exercise price per share of $[            ],
and requests that the certificates for such Warrant Shares be issued, subject to Sections 10 and 11, in the name of, and delivered to: 
  
  
  
  
  
  
  
  
 The undersigned is hereby
making payment for the Warrant Shares in the following manner: [check one] 
  

	 	 ̈	by cash in accordance with Section 3.1(b) of the Warrant 

  

	 	 ̈	via cashless exercise in accordance with Section 3.1(c) of the Warrant in the following manner: 

  
  
  
  
  
  
  
  
 The undersigned hereby represents
and warrants that it is, and has been since its acquisition of the Warrant, the record and beneficial owner of the Warrant. 
  

	
	 Dated:                                      
    

	
	 
	 Print or Type Name

	
	 
	(Signature must conform in all respects to name of holder as specified on the face of Warrant)
	
	 
	 (Street Address)

	
	 
	 (City)                                       
         (State)                 (Zip Code)

  

 13 

 EXHIBIT B 
 FORM OF ASSIGNMENT 
 [To be executed only upon transfer of Warrant]

 For value received, the undersigned registered holder of the within Warrant hereby sells, assigns and transfers unto
                     [include name and addresses] the rights represented by the Warrant to purchase
             Common Shares of MED BIOGENE INC. to which the Warrant relates, and appoints
                     Attorney to make such transfer on the books of MED BIOGENE INC. maintained for the purpose, with full power of substitution in
the premises. 
  

					
	 Dated:
	 	 	  	 
		 		  	(Signature must conform in all respects to name of holder as specified on the face of Warrant)
			
		 		  	 
		 		  	(Street Address)
			
		 		  	 
		 		  	(City)                                       
 (State)                (Zip Code)
		
	Signed in the presence of:	  	
		
		  	 
		 		  	(Signature of Transferee)
			
		 		  	 
		 		  	(Street Address)
			
		 		  	 
		 		  	(City)                                       
 (State)                (Zip Code)

  

 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]